Shots:
- 1ST Biotherapeutics SK Biopharmaceuticals have entered into an exclusive global licensing agreement & strategic equity investment partnership to advance 1ST-104 for the treatment of Parkinson’s disease
- As per the deal, 1STBIO will receive a $1.8M upfront payment, with the licensing agreement valued at ~$314.8M, incl. a $1.8M short-term milestone upon candidate selection & additional milestones
- Upon commercialization, 1STBIO will receive tiered royalties on global net sales, while SKBP has made a $2.2M strategic equity investment in 1STBIO to support a long-term partnership
Ref: PRnewswire | Image: 1ST Biotherapeutics SK Biopharmaceuticals | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
